FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
D000293:Adolescent; D000328:Adult; D002648:Child; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide